Literature DB >> 17053925

[Antiviral treatment regimens].

S Esser1.   

Abstract

The availability and use of effective antiretroviral combination therapies has dramatically decreased the morbidity and mortality of HIV infection. Almost complete suppression of viral replication by antiretroviral therapy prevents disease progression and development of resistance, as well as leading to both regression of HIV-associated symptoms and clinically relevant immune reconstitution. More than 20 antiretroviral substances in four classes have been approved. As a result of the broad therapeutic options, HIV infection can be better treated. Although a high number of combinations can be conceived, only a small number is actually applicable. The decisions to start, monitor and change therapy have become even more difficult. The indication for treatment, the selection of the most suitable therapy for an individual, the counseling of the patient, and the monitoring of the success of treatment demand a high level of knowledge and experience. Virologic failures of modern antiretroviral therapy regimens are rare in adherent patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053925     DOI: 10.1007/s00105-006-1224-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Tenofovir-related nephrotoxicity in HIV-infected patients.

Authors:  Ana Barrios; Teresa García-Benayas; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

3.  48-weeks of the RESIST trials.

Authors:  Pilar Garcia-Gasco
Journal:  AIDS Rev       Date:  2006 Jan-Mar       Impact factor: 2.500

4.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

Authors:  J S Montaner; P R Harrigan; N Jahnke; J Raboud; E Castillo; R S Hogg; B Yip; M Harris; V Montessori; M V O'Shaughnessy
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

5.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

6.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr; J Miller; M Law; D A Cooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

7.  German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004).

Authors:  B Salzberger; U Marcus; B Vielhaber; K Arasteh; J Gölz; N H Brockmeyer; J Rockstroh
Journal:  Eur J Med Res       Date:  2004-11-29       Impact factor: 2.175

8.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

10.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

Authors:  J M Raboud; J S Montaner; B Conway; S Rae; P Reiss; S Vella; D Cooper; J Lange; M Harris; M A Wainberg; P Robinson; M Myers; D Hall
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.